4d Pharma PLC Publication - microbiota as HDAC inhibitors
July 30 2018 - 1:01AM
RNS Non-Regulatory
TIDMDDDD
4d Pharma PLC
30 July 2018
4D pharma plc
(the "Company" or "4D")
4D announces publication of data showing potential of single
bacterial strains from the human gut microbiota to serve as novel
HDAC inhibitors
30 July 2018 -- 4D pharma plc (AIM: DDDD), a pharmaceutical
company leading the development of live biotherapeutics, today
announces the publication of data showing that specific single
bacterial strains from the human gut microbiota have the potential
to serve as therapeutic inhibitors of the human enzyme histone
deacetylase (HDAC), which is particularly relevant for disease
areas involving host epigenetic aberrations.
The paper, titled "Human gut bacteria as potent class I histone
deacetylase inhibitors in vitro through production of butyric acid
and valeric acid" (Yuille S., et al) is published in PLOS ONE, the
peer-reviewed open access scientific journal.
Overexpression of isoforms of HDAC has been implicated in a
variety of diseases, including cancer, colitis, cardiovascular
disease and neurodegeneration. HDAC inhibitors have a long history
as therapeutic targets and the gut microbiota is known to have an
influence on HDAC activity via microbial-derived metabolites. In
this study, researchers used an in vitro approach to screen the 4D
bacterial library to identify strains which inhibit different HDAC
isoforms. One identified strain, MRx0029, was added to a model
microbial consortium to assess its metabolic activity in
interaction with a complex bacterial community. They found that
MRx0029 successfully established in the consortium and enhanced the
total and specific HDAC inhibitory function by increasing the
capacity of the community to produce butyrate and valeric acid.
Dr. Alex Stevenson, 4D's Chief Scientific Officer, commented:
"This work shows that microbiome-derived live biotherapeutics can
inhibit specific HDAC activity via previously unknown mechanisms.
This could lead to new live biotherapeutic therapies targeting this
class of enzymes for conditions including cancer, neurodegenerative
disorders and inflammatory pathologies. Moreover, in developing a
model microbiome consortium, we have further demonstrated the
ability of single-strain live biotherapeutics to induce
community-wide functional changes in the microbiome and impact
disease-relevant host signaling pathways."
For further information please contact:
4D + 44 (0)113 895 0130
Duncan Peyton, Chief Executive Officer
Zeus Capital Limited - Nomad and Joint Broker
Dan Bate / Jordan Warburton +44 (0) 161 831 1512
Bryan Garnier & Co. Limited - Joint Broker +44 (0)20 7332 2500
Dominic Wilson
Phil Walker
About 4D
Founded in February 2014, 4D is a world leader in the
development of live biotherapeutics, a novel and emerging class of
drugs, defined by the FDA as biological products that contain a
live organism, such as a bacteria, that is applicable to the
prevention, treatment or cure of a disease. 4D has developed a
proprietary platform that rationally identifies novel bacteria that
have a precise and evolved therapeutic effect. All of 4D's live
biotherapeutic products are orally delivered single strains of
bacteria that are naturally found in the healthy human gut. 4D has
completed a phase I study in Irritable Bowel Syndrome and has
completed dosing in a phase I study in Paediatric Crohn's Disease.
It currently has a pipeline of 13 pre-clinical programmes, covering
disease areas such as cancer, poorly controlled asthma, autoimmune
and CNS disease, and plans to commence four additional clinical
studies in 2018. For more information, refer to
https://www.4dpharmaplc.com/.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRABSGDRCXDBGIR
(END) Dow Jones Newswires
July 30, 2018 02:01 ET (06:01 GMT)
4d Pharma (LSE:DDDD)
Historical Stock Chart
From Apr 2024 to May 2024
4d Pharma (LSE:DDDD)
Historical Stock Chart
From May 2023 to May 2024